OCT 16, 2018 10:00 PM PDT

Potential Targeted Treatment for Crohn Disease

WRITTEN BY: Nouran Amin

Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract.

Now, recent research at Cornell University and University of North Carolina (UNC) is a step closer to advancing drug treatments for CD patients. Such research proposes the potential targeting of a key molecule, called microRNA-31 (miR-31), which can predict if a patient has subtype 1 or subtype 2 of Crohn’s disease. This is particularly crucial because patients with subtype 1, unlike subtype 2, will often not respond to treatments which can lead to the surgical interventions for strictures – the extreme narrowing of the gut. With clinical markers like miR-31, healthcare providers may be able to better asses a CD patient if they should consider pre-emptive surgery before the condition worsens.

“We are not at the point at which we are able to perform personalized medicine on this, but at the very least we think it can lead to better clinical trial designs,” says Praveen Sethupathy, senior co-author of the study.

Previously, clinical trials assessing a new drug for CD has grouped all patients together causing inconsistent results. However, using miR-31, scientists are now able to separate individuals with CD into subtypes for better drug assessment. The results of the study published in the journal JCI Insight.

Credit: Drug Target Review

“Our study hints that it’s not only that miR-31 could be a predictive indicator of clinical outcome, but also that it could be functionally relevant in driving the disease,” explains Sethupathy.

Researchers are now hopeful for future studies that will determine the exact role of miR-31 in gut biology. “Our long-term goal, extending the work of this study, is to better understand at the molecular level why CD is so different in its presentation across patients, and to use this knowledge to develop more effective therapies,” says Terrence Furey, an associate professor of genetics.

Source: Drug Target Review

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 11, 2018
Drug Discovery
SEP 11, 2018
Widely-Used Drug Contributed To Skin Cancer
In a research study at the University of Dundee, Queen Mary University of London and the Wellcome Sanger Institute, a drug, by the name of azathioprine, wh...
OCT 05, 2018
Cancer
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
NOV 10, 2018
Genetics & Genomics
NOV 10, 2018
Scientists Engineer a Better Way to Direct Evolution
Directed evolution is a Nobel-prize winning technique that has now been simplified and accelerated....
NOV 13, 2018
Drug Discovery
NOV 13, 2018
Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful
Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Anti-inflammatory Drug Works Like an Inhibitor
At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor. The new anti-...
Loading Comments...